EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Enhanced cytotoxic effect of a glycoengineered monoclonal antibody targeting oncofetal chondroitin sulfate

Nanna Skeltved, Anne Martin-Salazar, Henri Oskar Kolz, Mary Lopez-Perez, Elena Ethel Vidal-Calvo, Swati Choudhary, Søren Skov, Ali Salanti, Robert Dagil

Cancer Immunology, Immunotherapy · 20.11.2026

DOI: 10.1007/s00262-026-04648-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 20.11.2026. Verfasst von Nanna Skeltved und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NEYE foundation, Danmarks Frie Forskningsfond, Novo Nordisk Fonden.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • NEYE foundation
  • Danmarks Frie Forskningsfond
  • Novo Nordisk Fonden
  • Innovationsfonden
  • Kræftens Bekæmpelse
  • Copenhagen University

Zitieren

APA

Skeltved, N., Martin-Salazar, A., Kolz, H. O., Lopez-Perez, M., Vidal-Calvo, E. E., Choudhary, S., Skov, S., Salanti, A., & Dagil, R. (2026). Enhanced cytotoxic effect of a glycoengineered monoclonal antibody targeting oncofetal chondroitin sulfate. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04648-w

Vancouver

Skeltved N, Martin-Salazar A, Kolz HO, Lopez-Perez M, Vidal-Calvo EE, Choudhary S, et al. Enhanced cytotoxic effect of a glycoengineered monoclonal antibody targeting oncofetal chondroitin sulfate. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04648-w

BibTeX
@article{Skeltved2026,
  author = {Skeltved, Nanna and Martin-Salazar, Anne and Kolz, Henri Oskar and Lopez-Perez, Mary and Vidal-Calvo, Elena Ethel and Choudhary, Swati and Skov, Søren and Salanti, Ali and Dagil, Robert},
  title = {Enhanced cytotoxic effect of a glycoengineered monoclonal antibody targeting oncofetal chondroitin sulfate},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04648-w}
}
Kostenlos starten →